Head-to-head · WeighScore
Elara MD vs Nucific
The verdict
Nucific takes it — 56.2/100 to 53.5/100.
Nucific grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GLP-1 and NAD+ telehealth founded by triple board-certified physician Dr.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Elara MD | Nucific |
|---|---|---|
| WeighScore | 53.5/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #466 | #417 |
| Semaglutide | $249/mo (0.2 mg dose, compounded) | Not disclosed |
| Tirzepatide | $349/mo (2.0 mg dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #466 · C
Strengths
- Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
- Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
- Medication included in the monthly price with free fast shipping when prescribed
- Broad reach claimed (over 40 states)
Where it loses points
- Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
- No FDA compounded-medication disclaimer published
- No named compounding pharmacy partner — prescriptions are patient-directed
- LegitScript certification, medical director, and full state list not disclosed
- Pricier than several compounded competitors
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.